Zydus Lifesciences Completes Tender Offer for Assertio Holdings Acquisition

Zydus Lifesciences Ltd. announced that it has successfully completed the cash tender offer to acquire all outstanding shares of Assertio Holdings, Inc., a U.S.-based pharmaceutical company listed on Nasdaq.

The acquisition was carried out through Zydus’ wholly-owned subsidiary, Zara Merger Sub Inc. Under the offer, shareholders of Assertio were offered $23.50 per share in cash, subject to applicable taxes.

Strong Shareholder Participation

The tender offer expired shortly after midnight (Eastern Time) on June 15, 2026. By the closing of the offer, around 4.29 million shares had been validly tendered and not withdrawn, representing approximately 66.32% of Assertio’s total outstanding shares.

Zydus has accepted all tendered shares for payment and expects to complete the payment process shortly.

Merger to Be Completed on June 16

The company plans to complete the acquisition through a merger on June 16, 2026. Following the merger, any remaining Assertio shares that were not tendered will be converted into the right to receive the same cash consideration of $23.50 per share, subject to applicable tax deductions.

After the transaction is completed, Assertio will become a wholly-owned subsidiary of Zydus Lifesciences. Its shares will also be delisted and will no longer trade on the Nasdaq Global Market.

About Zydus Lifesciences

Zydus Lifesciences is a global healthcare company engaged in the discovery, development, manufacturing, and marketing of a wide range of healthcare products. The company employs more than 29,000 people worldwide, including 1,500 researchers and scientists involved in research and development activities.

Over the years, Zydus has introduced several innovative healthcare solutions, including vaccines, biologics, therapeutics, and new chemical entities, with a focus on addressing unmet medical needs.

Read More: Vedanta Aluminium Shares Debuts at ₹522 Post-Demerger; Combined Value of 5 Entities Surpasses ₹930 Per Share!

Zydus Lifesciences Share Price Movement

On June 16, 2026, Zydus Lifesciences share price (NSE: ZYDUSLIFE) closed at ₹1,080.80, down 0.67% (₹7.30) from the previous session. The stock opened at ₹1,088.90 and touched an intraday high of ₹1,091.60 before slipping to a low of ₹1,072.40.  

Conclusion

The completion of the Assertio acquisition marks an important step in Zydus Lifesciences’ global expansion strategy. The deal is expected to strengthen Zydus' presence in the U.S. pharmaceutical market and enhance its portfolio, supporting the company's long-term growth ambitions in the healthcare sector.

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.